Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

Intellia Therapeutics, Inc. (Nasdaq: NTLA) today announced positive topline results from the landmark Phase 3 HAELO clinical trial evaluating lonvoguran ziclumeran (lonvo-z) for the treatment of hereditary angioedema (HAE). As the first global Phase 3 data reported for an in vivo CRISPR gene editing therapy, this milestone represents a profound advancement for precision medicine and patients suffering from recurrent, life-threatening swelling attacks.

Key HAELO Phase 3 Trial Highlights

• The HAELO trial met its primary endpoint, demonstrating an 87% reduction in swelling attacks compared to placebo over a six-month period.
• Most patients treated with a single dose of lonvo-z remained free from both HAE attacks and the need for ongoing prophylaxis therapy throughout the evaluation period.
• Intellia has initiated a rolling Biologics License Application (BLA) submission to the FDA, targeting a potential U.S. launch in the first half of 2027.
• Regulatory designations include RMAT and Orphan Drug, which facilitate expedited pathways for review and approval.

For more insights on the evolving Hereditary Angioedema treatment landscape, download Delveinsight's Hereditary Angioedema market report @ https://www.delveinsight.com/sample-request/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The Hereditary Angioedema Patient Population and Unmet Medical Need

Hereditary angioedema is a rare genetic disorder affecting approximately one in 50,000 people globally. The condition is characterized by severe, unpredictable inflammatory attacks resulting from an overproduction of bradykinin. These attacks can cause painful swelling in the face, extremities, and abdomen, and may become life-threatening if the airway is involved.

Despite current long-term prophylaxis options, many patients continue to experience breakthrough attacks and face a heavy treatment burden from frequent intravenous or subcutaneous administrations. Lonvo-z is designed as a one-time treatment administered in an outpatient setting to durably eliminate the need for chronic preventive therapies.

Explore more about HAE treatment trends and clinical pipeline progress @ https://www.delveinsight.com/sample-request/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The lonvo-z (lonvoguran ziclumeran) Mechanism

Lonvo-z is an in vivo CRISPR/Cas9-based gene editing candidate that works by inactivating the kallikrein B1 (KLKB1) gene. By silencing this gene, the therapy permanently lowers levels of kallikrein and bradykinin, addressing the root cause of swelling attacks. This innovative approach aims to reset the standard of care by providing a durable, potentially curative solution for HAE patients.

"The promising results from HAELO reinforce our conviction that lonvo-z could revolutionize how HAE is treated," said John Leonard, M.D., President and CEO of Intellia. "If approved, it will become the world's first in vivo CRISPR-based gene editing therapy, potentially freeing most patients from both attacks and the burden of chronic therapy with just one dose."

Clinical Validation and Safety Profile

The Phase 3 HAELO trial enrolled 80 adult and adolescent patients, with 52 receiving a single dose of lonvo-z. The treatment demonstrated a mean monthly attack rate of 0.26 compared to 2.10 in the placebo group. Safety data were favorable, with the most common adverse events being infusion-related reactions, headache, and fatigue. All reported adverse events were mild to moderate, and no serious adverse events occurred in the lonvo-z arm.

Understand the changing Hereditary Angioedema Pipeline @ https://www.delveinsight.com/sample-request/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Regulatory Path and Hereditary Angioedema Commercial Outlook

Intellia has already initiated a rolling BLA submission to the FDA, leveraging its RMAT designation and participation in the FDA's Chemistry, Manufacturing, and Controls (CMC) pilot program. The company expects to complete the BLA filing in the second half of 2026, with an anticipated U.S. launch in the first half of 2027. Additional data from the HAELO study will be presented at the 2026 European Academy of Allergy and Clinical Immunology (EAACI) Congress in June.

Conclusion: A New Era for Gene Editing

The successful completion of the HAELO Phase 3 trial establishes lonvo-z as a groundbreaking candidate in medicine, demonstrating the potential for in vivo CRISPR gene editing to offer a durable, one-time treatment for HAE. This achievement validates Intellia's platform and promises a paradigm shift for patients currently managing chronic, burdensome prophylaxis. As Intellia moves towards a potential U.S. launch in early 2027, the focus remains on realizing the transformative promise of gene editing for patients worldwide.

Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe, helping them stay ahead of the growth curve.

This release was published on openPR.